Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Weissfeld

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
The New England Journal of Medicine|May 24, 2018
A Randomized Trial of a Family-Support Intervention in Intensive Care UnitsDouglas B White, Derek C Angus, Anne-Marie Shields, et al.
Annals of Clinical and Translational Neurology|September 11, 2023
Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history dataDavid R Lynch, Angie Goldsberry, Christian Rummey, et al.
Critical Care Medicine|June 5, 2019
A Multicenter Study of the Causes and Consequences of Optimistic Expectations About Prognosis by Surrogate Decision-Makers in ICUsDouglas B White, Shannon Carson, Wendy Anderson, et al.
The Lancet. Neurology|July 4, 2015
Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort studyWai-Ying Wendy Yau, Dana L Tudorascu, Eric M McDade, et al.
The Lancet. Microbe|December 4, 2025
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussisDiane Gbesemete, Maheshi N Ramasamy, Muktar Ibrahim, et al.
Lancet (London, England)|August 15, 2017
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trialDaniel S Ory, Elizabeth A Ottinger, Nicole Yanjanin Farhat, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
The New England Journal of Medicine|May 24, 2018
A Randomized Trial of a Family-Support Intervention in Intensive Care UnitsDouglas B White, Derek C Angus, Anne-Marie Shields, et al.
Annals of Clinical and Translational Neurology|September 11, 2023
Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history dataDavid R Lynch, Angie Goldsberry, Christian Rummey, et al.
Critical Care Medicine|June 5, 2019
A Multicenter Study of the Causes and Consequences of Optimistic Expectations About Prognosis by Surrogate Decision-Makers in ICUsDouglas B White, Shannon Carson, Wendy Anderson, et al.
The Lancet. Neurology|July 4, 2015
Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort studyWai-Ying Wendy Yau, Dana L Tudorascu, Eric M McDade, et al.
The Lancet. Microbe|December 4, 2025
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussisDiane Gbesemete, Maheshi N Ramasamy, Muktar Ibrahim, et al.
Lancet (London, England)|August 15, 2017
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trialDaniel S Ory, Elizabeth A Ottinger, Nicole Yanjanin Farhat, et al.
Pageof 6